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ABSTRACT
Objectives: To describe our experience with laparo-
scopic primary or interval tumor debulking in patients
with presumed advanced ovarian, fallopian tube, or peri-
toneal cancers.
Methods: This is a retrospective analysis of a prospective
case series. Women with presumed advanced (FIGO stage
IIC or greater) ovarian, fallopian tube, or primary perito-
neal cancers deemed appropriate candidates for laparo-
scopic debulking by the primary surgeon(s) were re-
cruited.
Results: The study comprised 32 patients who underwent
laparoscopic evaluation. Seventeen underwent total lapa-
roscopic primary or interval cytoreduction, with 88.2%
optimal cytoreduction. Eleven underwent diagnostic lapa-
roscopy and conversion to laparotomy for cytoreduction,
with 72.7% optimal cytoreduction. Four patients had bi-
opsies, limited cytoreduction, or both. In the laparoscopy
group, 9 patients have no evidence of disease (NED), 6
are alive with disease (AWD), and 2 have died of disease
(DOD), with mean follow-up time of 19.7 months. In the
laparotomy group, 3 patients are NED, 5 are AWD, and 3
are DOD, with mean follow-up of 25.8 months. Estimated
blood loss and length of hospital stay were less for the
laparoscopy group (P0.008 and P0.03), while operat-
ing time and complication rates were not different. Me-
dian time to recurrence was 31.7 months for the laparos-
copy group and 21.5 months for the laparotomy group
(P0.3).
Conclusions: Laparoscopy can be used for diagnosis,
triage, and debulking of patients with advanced ovarian,
fallopian tube, or primary peritoneal cancer and is tech-
nically feasible in a well-selected population.
Key Words: Laparoscopy, Ovarian Cancer, Cytoreduc-
tion.
INTRODUCTION
In the United States, ovarian cancer will affect approxi-
mately 21,550 women in 2009 with 14,600 estimated
deaths.1 Approximately 70% of patients are diagnosed
with extraovarian disease. The traditional approach to
manage patients with ovarian cancer involves midline
laparotomy, hysterectomy, bilateral salpingo-oophorec-
tomy (BSO), omentectomy, peritoneal biopsies, diaphrag-
matic scrapings, bilateral pelvic and para-aortic lymph
node sampling, and maximal debulking effort with the
intent of leaving “no visible disease,” followed by chemo-
therapy. Optimal cytoreductive surgery has been consis-
tently shown to have a significant survival benefit in the
setting of primary advanced ovarian cancer.2 In patients
with disease thought not to be optimally resectable, the
use of neoadjuvant chemotherapy to reduce tumor load
can allow for interval surgical debulking.3
Advances in laparoscopic surgery have extended this min-
imally invasive surgical approach to managing ovarian
cancer. In early stage ovarian cancer, multiple studies
have demonstrated feasibility and efficacy of complete
laparoscopic staging.4-14 Laparoscopy offers several ad-
vantages to traditional open surgery: optical magnification
of abdominal and pelvic anatomy, ease in visualization of
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SCIENTIFIC PAPERSthe diaphragm and peritoneal surfaces, shorter postoper-
ative recovery, and a decrease in length of hospital stay.4
In advanced stage ovarian cancer, the role of laparoscopy
has been described as a tool to triage for resectability and
second-look evaluations, with limited studies on its role in
cytoreductive procedures. The objective of this study was
to describe our preliminary experience with laparoscopic
total primary or interval cytoreduction in patients with
advanced ovarian, fallopian, and primary peritoneal can-
cers.
MATERIALS AND METHODS
Patients
Select women with confirmed or suspected advanced
ovarian cancer (FIGO stage IIC) presenting to authors
(FN, HG, LC) from January 2005 to June 2009 at their
affiliated medical centers underwent exploratory laparos-
copy and biopsy, followed by subsequent primary or
interval cytoreduction by laparoscopy or laparotomy fol-
lowing laparoscopic assessment. Women were recruited
who were medically stable enough to undergo surgery
and were judged by the primary surgeon(s) to be good
candidates for laparoscopic debulking. Among those pa-
tients presenting with suspected primary advanced ovar-
ian cancer, exploratory laparoscopy was offered to con-
firm the diagnosis and to assess the possibility of optimal
laparoscopic or open cytoreductive surgery with a goal of
no residual disease. All patients underwent preoperative
evaluation including history, physical examination, med-
ical assessment, and imaging of the chest, abdomen, and
pelvis. All patients were counseled extensively preopera-
tively and appropriate informed consent was obtained.
During the initial intraoperative assessment, the decision
to proceed with a total laparoscopic approach was made
by the treating physician. Factors influencing the surgical
approach included extent of disease, location of tumor,
and medical comorbidities. Only patients with gross ex-
traovarian disease were included in this study. Patients
were discharged from the hospital when they were med-
ically stable and able to tolerate oral intake well. Intrave-
nous or intraperitoneal standard chemotherapy was
started as soon as the patients were able to tolerate it. All
patients were followed every 3 months to 4 months with
complete physical examination, measurement of tumor
markers, and imaging studies as needed. Subsequent sur-
gery and chemotherapies were initiated as standard prac-
tice.
Outcome variables analyzed included histology, stage,
site of disease, extent of debulking, operative time, blood
loss, length of hospital stay, complications, follow-up du-
ration, and survival time. Pathology, operative reports,
hospital and office charts were reviewed retrospectively
upon approval by the institutional review board. Postop-
erative complications were defined as adverse events oc-
curring within 30 days of surgery. Optimal cytoreduction
was defined as residual disease 1 cm. Recurrence of
disease was defined as recurrence after a period of at least
6 months with no evidence of disease. Statistical analysis
was performed using Systat 12.0. The Kaplan-Meier esti-
mator was used to estimate disease-free survival. The
2-sample t test and the Wilcoxon rank sum test were used
for continuous variables, as appropriate. Results were
considered significant if P0.05.
Surgical Technique
All procedures were performed using a multiple puncture
operative laparoscopy with the patient under general an-
esthesia.15 Initial closed transumbilical or left upper quad-
rant (Palmer’s point) entry using a Veress needle was
utilized in most patients. Alternatively, periumbilical cut-
down and balloon trocar was utilized. All patients re-
ceived one dose of preoperative antibiotic therapy. The
surgical principles used for staging and tumor debulking
during laparotomy were followed. The procedure began
with careful inspection of the abdomen and pelvis. If
extraovarian disease was noted, that patient was included
in this study. Following the initial survey of the abdomen
and pelvis, aspiration of any pelvic ascites or peritoneal
washings was performed and submitted for cytologic eval-
uation. If there was no preoperative diagnosis of ovarian,
fallopian tube, or primary peritoneal carcinoma, appropri-
ate biopsies were performed and sent for frozen section
evaluation. Upon a diagnosis of primary ovarian, fallopian
tube, or peritoneal carcinoma, staging and cytoreduction
procedures were performed either laparoscopically or via
laparotomy, depending on the treating physician’s deci-
sion, the patient’s medical condition, and the extent of
disease. Staging and debulking consisted of hysterectomy,
BSO, resection of bulky pelvic and para-aortic lymph
nodes, and radical debulking of metastatic tumor, includ-
ing bowel resection and diaphragm ablation with resec-
tion, with a goal of no visible disease.16 Different laparo-
scopic instruments and techniques were used to achieve
optimal cytoreduction, including sharp scissors, electro-
surgery, CO2 laser, PlasmaJet (Plasma Surgical Limited,
Oxfordshire, UK), and argon beam coagulator.15 Rectosig-
moid colon resection, where necessary, was performed
first by mobilizing the descending colon to the level of the
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performed proximally and distally utilizing a 60-mm GIA
stapler. The mobilized proximal sigmoid colon was
brought out through the vagina after the hysterectomy
portion was completed, and an anvil was placed and
secured by using a purse string suture. The anvil was then
placed back into the peritoneal cavity, and the vagina
closed laparoscopically. A 33-mm EEA stapler was passed
into the rectum, and the spike was deployed, connected
to the anvil and activated, creating an end-to-end anasto-
mosis. Clamping the proximal colon with a bowel grasper,
the anastomosis site was tested by filling the pelvis with
lactated Ringer’s solution and, under observation with the
laparoscope, insufflating the rectum with air to check for
leakage. The site was also tested by filling the rectum with
indigo carmine and examining for leakage.15
All specimens were placed in endoscopic bags and re-
moved vaginally or extracted from the abdomen prior to
terminating the procedure. The port sites were irrigated
and a full thickness closure was performed to possibly
decrease trocar-site metastasis.
RESULTS
Included in this study were 32 patients who initially un-
derwent laparoscopic evaluation. They were subse-
quently divided into 3 groups: (1) primary cytoreduction
and interval debulking via laparoscopy, (2) diagnostic
laparoscopy followed by primary cytoreduction and de-
bulking via laparotomy, and (3) diagnostic laparoscopy
and biopsies. Four patients underwent diagnostic laparos-
copies and subsequent biopsies, limited surgical cytore-
duction, or both of these. Two of these patients were
diagnosed with gastrointestinal primary malignancies, and
after diagnosis were excluded and referred to medical
oncologists. The third patient in this group had primary
peritoneal adenocarcinoma and underwent laparoscopy
with pelvic washings, biopsies, and BSO. Because of her
advanced age of 90 years and multiple medical comor-
bidities, the patient had preoperatively declined surgical
debulking surgery. She underwent neoadjuvant chemo-
therapy and developed partial small bowel obstruction
(SBO) 11 months later. She is alive with disease (AWD) at
last follow-up. The fourth patient underwent laparo-
scopic-assisted vaginal hysterectomy (LAVH), BSO, and
omentectomy and was diagnosed with benign disease,
struma ovarii. None of these patients had intra- or post-
operative complications.
Comparison of patient and tumor characteristics in the
cytoreduction groups by laparoscopy and laparotomy
shows no statistically significant differences in age, body
mass index (BMI), or histologies (Table 1).
Laparoscopic Primary Cytoreduction
Seventeen patients with abdominal, or pelvic masses, or
both, suspicious for advanced ovarian cancer underwent
total laparoscopic primary or interval cytoreduction
(Table 2). Overall extent of disease, assessed grossly, re-
vealed 9 patients with upper abdominal disease and 8 pa-
tients with initial disease confined to the pelvis. All patients
were surgically stage IIIA or greater, with 2 being stage IV.
Fifteen of the 17 patients were optimally cytoreduced to
0.5 cm of residual disease (88.2%), including 4 who
were cytoreduced to microscopic disease. Four of the 15
patients who were optimally cytoreduced (#1, #9, #10,
#13) had interval laparoscopic debulking, 2 patients to
microscopic disease and 2 to 0.5 cm of residual disease.
Two patients (#5, #15) were not optimally cytoreduced
due to medical conditions. One patient was 85 years old
with stage IV disease and bowel obstruction, and preop-
eratively declined aggressive surgical management. The
other patient had multiple pulmonary embolisms diag-
nosed preoperatively and could not medically tolerate
prolonged surgery. The operation was performed in this
patient to confirm the diagnosis and remove a large symp-
tomatic pelvic mass.
The operative procedures for each patient are listed in
Table 3. The mean operative time (OR time) was 307.0
Table 1.
Patient Characteristics
Variables* Group 1
Laparoscopy
(n17)
Group 2
Laparoscopy/
Laparotomy
(n11)
P Value*
Age (years) 60.9  14.8 65.6  11.4 NS
BMI (kg/m
2) 35.9  17.9 30.6  5.0 NS
Histologic type NS
Serous 13 (76.5%) 7 (63.6%)
Adenocarcinoma 2 (11.8%) 2 (18.2%)
Endometrioid 1 (5.9%) 0
Clear cell 1 (5.9%) 0
Mixed 0 1 (9.1%)
MMMT 0 1 (9.1%)
*BMIbody mass index; MMMTmalignant mixed Müllerian
tumor; NS  not significant.
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mated blood loss (EBL) ranged from 10 mL to 500 mL with
a mean of 247.6 mL. Overall mean hospital length of stay
(LOS) was 6.1 days, with a range of 1 day to 24 days. Two
patients had LOS of 16 days and 24 days. The prolonged
LOS was secondary to other medical conditions and not
due to the surgical procedures performed. One patient
was septic preoperatively as a result of bowel obstruction
from a tumor, and the other patient had pulmonary em-
bolisms preoperatively that required medical therapy.
With exclusion of these 2 patients in the assessment of
LOS, the mean is 3.8 days, with a range of 1 day to 7 days.
One intraoperative complication occurred in patient #2
where the right ureter was transected. This patient had
extensive endometriosis with distorted anatomy, limiting
identification of the ureter. The injury was noted intraop-
eratively and repaired laparoscopically with a ureterone-
ocystotomy. Four patients had 6 postoperative complica-
tions. Patient #1 had symptomatic lymphocele that
required paracentesis. Patients #8, #10, and #17 had post-
operative ileuses that were managed conservatively. Pa-
tient #8 also had diverticular perforation 12 days after her
initial operation and her first course of intravenous che-
motherapy. She presented with rectal bleeding and had
evidence of air and a pelvic collection on CT scan. Ex-
ploratory laparoscopy revealed perforated sigmoid diver-
ticulum. The perforation and an incidental cystotomy
were repaired, and a colostomy was placed.15 She subse-
quently developed a vesicovagina fistula, which was re-
paired at the time of colostomy reversal 5 months later.
Patient #17 had temporary urinary retention, which re-
solved with conservative prolonged bladder catheteriza-
tion management.
In addition, there were 2 delayed postoperative compli-
cations that occurred more than 30 days after surgery, in
patients #3 and #7. Patient #3 experienced vaginal cuff
dehiscence with small bowel evisceration 4 months post-
operatively, requiring immediate surgical repair. She had a
subsequent recurrence at the vaginal cuff at 15 months
postoperatively that was also surgically resected. She is
AWD at 19-month follow-up. Patient #7 had a vesicovag-
inal fistula 3 months postoperatively that was successfully
repaired laparoscopically after she completed intraperito-
Table 2.
Laparoscopy Group
Patient Age Stage, Grade, Pathology Extent of Disease (Gross) Extent of Debulking
1 46 IV grade 3 Adenocarcinoma ovarian No gross disease Optimal microscopic
2 44 IIIC Endometrioid adenocarcinoma ovarian Pelvis Optimal 0.5 cm
3 35 IIIC Papillary serous ovarian Pelvis Optimal 0.5 cm
4 63 IIIA Papillary serous ovarian Pelvis Optimal 0.5 cm
5 85 IV poorly differentiates Adenocarcinoma ovarian Pelvis, Upper Abdomen Suboptimal
6 76 IIIC Papillary serous primary peritoneal Pelvis, Upper Abdomen Optimal 0.5 cm
7 46 III grade 2 Papillary serous ovarian Pelvis, Upper Abdomen Optimal 0.5 cm
8 70 IIIC poorly differentiated Papillary serous ovarian Pelvis, Upper Abdomen Optimal 0.5 cm
9 80 IIIC Papillary serous ovarian fallopian tube Pelvis Optimal microscopic
10 60 IIIC Papillary serous, clear cell ovarian Pelvis, Upper Abdomen Optimal 0.5 cm
11 49 IIIC high grade Papillary serous ovarian Pelvis, Upper Abdomen Optimal 0.5 cm
12 72 IIIC grade 2 Papillary serous ovarian Pelvis Optimal 0.5 cm
13 79 IIIC poorly differentiated Papillary serous primary peritoneal Pelvis, Upper Abdomen Optimal 0.5 cm
14 67 IIIC Papillary serous ovarian Pelvis Optimal 0.5 cm
Synchronous IB endometrial
15 49 IIIC Clear cell adenocarcinoma ovarian Pelvis Suboptimal
16 52 IIIC high grade Papillary serous ovarian Pelvis, Upper Abdomen Optimal microscopic
17 62 IIIC Papillary serous ovarian Pelvis, Upper Abdomen Optimal microscopic
Synchronous IA endometrial
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JSLS (2010)14:155–168 160neal chemotherapy. At that time, the patient did not have
any evidence of disease.
None of the patients had trocar complications including
port-site metastases. Of these 17 patients, 9 are with no
evidence of disease (NED), 6 are AWD, and 2 have died of
disease (DOD). Mean follow-up time for these patients is
19.7 months, with a range of 1 month to 45 months.
Exploratory Laparoscopy and Open Primary
Cytoreduction
Eleven patients were converted to laparotomy for cytore-
duction after diagnostic laparoscopy due to the extent of
disease at the discretion of the operating surgeon
(Table 4). Eight of these patients were optimally reduced
to 1 cm of residual disease (72.7%). Specifically, 3 pa-
tients were reduced to between 5 mm and 1 cm, 4 to 0.5
cm, and 1 to microscopic disease. Patients #5, #6, and #7
had suboptimal debulking with BSO by laparotomy. Pa-
tients #5 and #7 received intravenous chemotherapy for 8
cycles and then underwent complete laparoscopic de-
bulking at 8 months. Patient #5 underwent total laparo-
scopic hysterectomy (TLH), bilateral pelvic lymph node
dissection, omentectomy, and colostomy reversal, and
had no pathological disease. Patient #7 underwent TLH
and right pelvic lymphadenectomy, and had microscopic
disease. Patient #6 also received intravenous chemother-
apy, and underwent secondary laparoscopic debulking
including omentectomy for recurrence at 17 months.
Overall extent of disease for all patients revealed all but
one patient with upper abdominal disease in addition to
pelvic disease. All patients but one had IIIC disease; the
other patient had IIIB. The operative procedures for each
patient are listed in Table 5. Mean OR time was 241.3
minutes with a range of 142 minutes to 382 minutes.
Estimated blood loss ranged from 300 mL to 1500 mL with
a mean of 609 mL. Mean LOS was 8.2 days, with a range
of 3 days to 14 days.
Two intraoperative complications occurred in this group.
Cystotomy occurred in patient #5, which was repaired,
with no further complications. Patient #11 had blood loss
of 1.5L that required transfusion of 4 units PRBCs. Five
patients had 7 postoperative complications. Patients #3,
#5, and #7 had ileus, one managed with a nasogastric tube
(NGT) and the other 2 with bowel rest. Patient #8 had a
pleural effusion and a small wound separation. She was
taken back to the operating room at an outside hospital 15
days postoperatively for suspected bowel perforation, af-
ter presenting to the emergency room with abdominal
pain. Patients #5 and #9 had pulmonary emboli, with
subsequent placement of an IVC filter in patient #9. None
of the patients had trocar complications including port-site
metastases. Of these 11 patients, 3 are NED, 5 are AWD,
and 3 are DOD. Mean follow-up time for these patients is
25.8 months, with a range of 5 months to 50 months.
Comparison of the laparoscopic debulking group with the
laparoscopy/laparotomy debulking group with respect to
OR time, EBL, LOS, and complications shows statistically
significant differences for EBL and LOS only, with the
Table 4.
Laparoscopy/Laparotomy Group
Patient Age Stage, Grade, Pathology* Extent of Disease (Gross) Extent of Debulking
1 65 IIIC Papillary serous ovarian Pelvis, Upper Abdomen Optimal 0.5 cm
2 51 IIIB Papillary serous ovarian Pelvis, Upper Abdomen Optimal 0.5 cm
3 70 IIIC Serous, mucinous, and endometrioid ovarian Pelvis Optimal microscopic
4 67 IIIC poorly differentiated Papillary serous ovarian Pelvis, Upper Abdomen Optimal 1c m
5 85 IIIC Adenocarcinoma ovarian Pelvis, Upper Abdomen Suboptimal
6 54 IIIC Papillary serous ovarian Pelvis, Upper Abdomen Suboptimal
7 79 IIIC Papillary serous ovarian Pelvis, Upper Abdomen Suboptimal
8 71 IIIC grade 3 Serous and clear cell ovarian Pelvis, Upper Abdomen Optimal 1c m
9 62 IIIC poorly differentiated Papillary serous ovarian Pelvis, Upper Abdomen Optimal 0.5 cm
10 48 IIIC high grade Papillary serous ovarian Pelvis, Upper Abdomen Optimal 0.5 cm
11 69 IIIC MMMT ovarian Pelvis, Upper Abdomen Suboptimal
*MMMTmalignant mixed Müllerian tumor.
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JSLS (2010)14:155–168 163laparoscopy group having less EBL and LOS (Table 6).
Kaplan-Meier analysis of the median time to recurrence in
the laparoscopy group was 31.7 months, and for the
laparoscopy/laparotomy group 21.5 months (Figure 1).
Although not statistically significant (P0.3), there ap-
pears to be a trend to greater time to recurrence in the
laparoscopy group.
DISCUSSION
Applications of laparoscopy in advanced ovarian cancer
have been described in triage for resectability, second-
look assessment, and, in select cases, primary and sec-
ondary cytoreduction[b].17,18 Thorough staging proce-
dures, and optimal cytoreduction, provide both essential
prognostic information and confer a survival benefit to
those who have microscopic postoperative disease.19,20 In
situations where the ability to achieve an optimal cytore-
duction is unlikely, neoadjuvant chemotherapy followed
by interval cytoreduction may be appropriate.3 Thus, lapa-
roscopy offers a less morbid approach for determining
which patients will likely have suboptimal cytoreduction
at the time of primary surgery and hence benefit from
neoadjuvant chemotherapy. Vergote et al21 reported a
series of 285 patients who underwent open laparoscopy
to determine whether optimal debulking is possible. They
found a 96% accuracy of prediction of tumor resectability.
Fagotti22 reported a subsequent study where patients un-
derwent laparoscopy followed by immediate laparotomy
to compare the intraoperative impression of resectability.
They found that 87% of patients deemed resectable at
laparoscopy were optimally debulked at laparotomy. Ad-
ditionally, no cases of unresectable disease at laparoscopy
Figure 1. Recurrence
Table 6.
Surgical Outcomes
Variables Group 1 Laparoscopy
(n17)
Group 2 Laparoscopy/Laparotomy
(n11)
P Value
Operative time (min) 307.0  140.6 241.3  85.3 NS
Estimated blood loss (mL) 247.6  140.9 609.1  31.1 .008
Hospital length of stay (days)
All 6.1  5.8 8.2  3.1 .03
Excluding 2 from LSC*
group
3.8  2.5 8.2  3.1 .003
Complications (%)
Intraoperative 1 (5.9%) 2 (18.2%) NS
Postoperative 6 (35.3%) 7 (63.6%) NS
*LSCLaparoscopy
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JSLS (2010)14:155–168 164were deemed resectable at subsequent laparotomy, yield-
ing a negative predictive value of 100%. Angioli et al23
reported a significant improvement in rate of optimal
debulking from 61% to 96% with the use of open laparos-
copy to determine suitability for cytoreductive surgery.
The shorter recovery period associated with laparoscopic
surgery compared with recovery for laparotomy also adds
the benefit of a shorter interval to commencing chemo-
therapy. In fact, select patients may begin neoadjuvant
chemotherapy the day after surgery.
Advances in laparoscopic instrumentation and technique
have made a laparoscopic approach to surgical cytoreduc-
tion possible in select patients. The first report of success-
ful laparoscopic cytoreduction in advanced ovarian can-
cer was described by Amara and Nezhat et al. 24 This case
series included 5 patients who underwent successful total
laparoscopic primary staging or secondary cytoreduction.
All patients did well postoperatively. One patient subse-
quently expired due to recurrent disease, declining further
intervention. The remaining literature on laparoscopic pri-
mary staging of advanced ovarian cancer involves the use
of hand-assisted laparoscopic surgery (HALS). In this tech-
nique, a combination of operative laparoscopy and mini-
laparotomy is utilized. A hand is introduced intraperitoneally
during laparoscopy to facilitate specimen extraction, tissue
manipulation, and retention of tactile sensation. Krivak et al18
reported the first case series of 25 patients who underwent
HALS for the treatment of advanced ovarian cancer. They
achieved optimal cytoreduction in 22/25 (88%) patients.
Among the 9 with gross disease noted on initial inspection,
6 patients (3 stage II and 3 stage III) were successfully
optimally debulked with hand-assisted laparoscopy. The re-
maining 3 patients required conversion to laparotomy: one
had extensive upper abdominal disease, one required a
modified posterior exenteration due to bulky pelvic disease,
and the last had extensive abdominal adhesions. We report
the largest case series utilizing laparoscopic surgery in as-
sessing the resectability and its ability to debulk advanced
ovarian, fallopian, and primary peritoneal cancers.
Laparoscopic debulking is feasible for upper abdominal
diseases. This may include resection of bulky omental
diseases and ablation of diaphragmatic implants. In our
series of a primary laparoscopic cytoreduction group, 9 of
17 patients had upper abdominal disease in addition to
pelvic involvement during laparoscopic evaluation. In the
laparoscopy/laparotomy cytoreduction group, 10 of 11
patients had upper abdominal disease in addition to pel-
vic disease. In our series, other procedures including
bowel resection, peritonectomy, diaphragm stripping, and
ureteral resection were performed in addition to the stan-
dard staging/debulking surgery (Tables 2 and 4). De-
spite the widespread extent of disease and radical nature
of some procedures, the overall mean OR time of 307
minutes, length of hospitalization, and complication rate
are comparable to those reported for open procedures.25
Several of our patients had intra- and postoperative com-
plications that required surgical repair. These were per-
formed laparoscopically, including a ureteroneocystos-
tomy, repair of cystotomy, and repair of diverticular
perforation. In addition, vaginal cuff dehiscence with
small bowel evisceration at 4 months postoperatively in
one of our patients was repaired laparoscopically. Nezhat
et al26 published in 1996 the first case series of 3 women
with vaginal evisceration after total laparoscopic hyster-
ectomy, 2 months to 5 months postoperatively. Two were
repaired via the vaginal route, and the third laparoscopi-
cally. A vesicovaginal fistula in another patient was also
successfully repaired laparoscopically. In 1994, a case
report of laparoscopic repair of a vesicovaginal fistula was
reported by Nezhat et al.27
In our series, we observed a longer recurrence-free inter-
val in the group of patients who underwent laparoscopic
debulking, 31.7 months versus 21.5 months (Figure 1).
Animal studies28 have shown that surgery can promote
metastasis and that invasiveness of the surgery is directly
proportional to the degree of metastasis. Animal and hu-
man studies29,30 have also shown that less postoperative
immunosuppression occurs after laparoscopic surgery
compared with laparotomy, and that immune homeostasis
is restored earlier in patients who have undergone lapa-
roscopic surgery. These immune factors, specifically cell-
mediated immunity, are proposed to possibly influence
cancer recurrence. This may explain the longer time to
recurrence in our laparoscopy patients. In addition, the
patients who had laparoscopic debulking were able to
commence chemotherapy earlier than the patients who
had laparotomy.
However, our study has its limitations. Our patients were
not randomized to laparoscopic cytoreduction, but rather,
selected for the procedure by the treating physician,
which may account for the high rate of optimal debulking.
Upon deciding that the patient was a candidate for cytore-
ductive surgery, the feasibility of laparoscopic cytoreduc-
tion was determined by the surgeon.
Additional concerns about the application of laparos-
copy in advanced ovarian cancer include inadequate
resection, carbon dioxide mediated dissemination, and
port-site metastases. This series demonstrates that com-
plete laparoscopic management of intestinal, ureteral,
JSLS (2010)14:155–168 165or retroperitoneal involvement is possible with sur-
geons proficient in advanced laparoscopy, thus render-
ing the suggestion of inadequate resection moot. Car-
bon dioxide pneumoperitoneum has been suggested to
lead to stimulation of ovarian cancer cell line growth.
Smidt et al31 reported that carbon dioxide promoted in
vitro growth in the ovarian epithelial carcinoma cell line
SKOV-3. However, few studies have examined the ef-
fect of carbon dioxide in humans. Abu-Rustum32 com-
pared the survival of 289 patients with persistent ovar-
ian or primary peritoneal cancers who underwent
second-look procedures either with laparoscopy or lap-
arotomy. There were no differences in the overall sur-
vival. They concluded that carbon dioxide exerts no
adverse effects on patient survival. In regards to the
possibility of port-site metastases, such events have
been reported in up to 16% of cases.33 No port-site
metastases have been noted in our patients to date.
However, it has been suggested that a higher risk of
port-site metastases occurs among patients with as-
cites.34 Techniques that may lower the risk of port-site
metastases include intact removal of the specimen in an
endoscopic bag and layered closure of the trocar site.33
These tactics were implemented into the surgical tech-
nique used in this study.
CONCLUSION
In summary, the role of laparoscopy in advanced ovarian,
fallopian, and primary peritoneal cancers is (1) to rule out
benign and non-Mu ¨llerian malignancies and (2) to assess
the extent of resectability either by laparoscopy or lapa-
rotomy, and to assess the option for neoadjuvant chemo-
therapy followed by cytoreduction. Our cohort suggests
that laparoscopic optimal cytoreduction in patients with
advanced ovarian, fallopian, and primary peritoneal can-
cers is technically feasible with acceptable morbidity in a
well-selected population either upfront or after neoadju-
vant chemotherapy. Furthermore, there may be a greater
time to recurrence in patients who have undergone lapa-
roscopic cytoreduction. The clinical paradigm imple-
mented in this study is illustrated in Figure 2. This algo-
rithm may be used as a guide in future studies to evaluate
the continuously expanding role of laparoscopy in pa-
tients with ovarian, fallopian, and primary peritoneal can-
cers.
References:
1. US National Institutes of Health National Cancer Insti
tute. Ovarian Cancer. Available at: http://www.cancer.gov/
cancertopics/types/ovarian Accessed Jan 3, 2010.
Figure 2. Clinical paradigm implemented in the present study.
The Safety and Efficacy of Laparoscopic Surgical Staging and Debulking of Apparent Advanced Stage Ovarian, Fallopian Tube, and
Primary Peritoneal Cancers, Nezhat FR et al.
JSLS (2010)14:155–168 1662. Bristow RE, Montz FJ, Lagasse LD, et al. Survival impact of
surgical cytoreduction in stage IV epithelial ovarian cancer. Gy-
necol Oncol. 1999;72:278.
3. Vergote I, van Gorp T, Amant F, Leunen K, Neven P, Ber-
teloot P. Timing of debulking surgery in advanced ovarian can-
cer. Int J Gynecol Cancer. 2008;18 suppl 1:11-19.
4. Nezhat FR, Ezzati M, Chuang L, Shamshirsaz AA, Rahaman J,
Gretz H. Laparoscopic management of early ovarian and fallo-
pian tube cancers: surgical and survival outcome. Am J Obstet
Gynecol. 2009;200:83.e1–e6.
5. Querleu D, LeBlanc E. Laparoscopic infrarenal paraaortic
lymph node dissection for restaging of carcinoma of the ovary or
fallopian tube. Cancer. 1994;73:1467-1471.
6. Childers JM, Lang J, Surwit EA, Hatch KD. Laparoscopic
surgical staging of ovarian cancer. Gynecol Oncol. 1995;59:
25-33.
7. Leblanc E, Querleu D, Narducci F, Occelli B, Papageorgiou
T, Sonoda Y. Laparoscopic restaging of early stage invasive
adnexal tumors: a 10-year experience. Gynecol Oncol. 2004;94:
624-629.
8. Chi DS, Abu-Rustum NR, Sonoda Y, et al. The safety and
efficacy of laparoscopic surgical staging of apparent stage I
ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005;
192:1614-1619.
9. Tozzi R, Kohler C, Ferrara A, Schneider A. Laparoscopic
treatment of early ovarian cancer: surgical and survival out-
comes. Gynecol Oncol. 2004;93:199-203.
10. Spirtos NM, Eisekop SM, Boike G, Schlaerth JB, Cappellari
JO. Laparoscopic staging in patients with incompletely staged
cancers of the uterus, ovary, fallopian tube, and primary perito-
neum: a Gynecologic Oncology Group (GOG) study. Am J
Obstet Gynecol. 2005;193:1645-1649.
11. Leblanc E, Sonoda Y, Narducci F, Ferron G, Querleu D.
Laparoscopic staging of early ovarian carcinoma. Curr Opin
Obstet Gynecol. 2006;18:407-412.
12. Pomel C, Provencher D, Dauplat J, et al. Laparoscopic stag-
ing of early ovarian cancer. Gynecol Oncol. 1995;58:301-306.
13. Ghezzi F, Cromi A, Uccella S, et al. Laparoscopy versus
laparotomy for the surgical management of apparent early stage
ovarian cancer. Gynecol Oncol. 2007;105:409-413.
14. Leblanc E, Querleu D, Narducci F, et al. Surgical staging of
early invasive epithelial ovarian tumors. Semin Surg Oncol. 2000;
19:36-41.
15. Nezhat C, Nezhat F, Nezhat C. Nezhat’s Operative Gyneco-
logic Laparoscopy and Hysteroscopy. 3rd ed. New York; Cam-
bridge University Press; 2008.
16. Katz VL, Lentz GM, Lobo RA, Gershenson DM. Comprehen-
sive Gynecology. 5th ed. Philadelphia; Mosby Elsevier; 2007.
17. Liu CS, Nagarsheth NP, Nezhat FR. Laparoscopy in ovarian
cancer: a paradigm change in the management of ovarian can-
cer. J Minim Invasive Gynecol. 2009;16:250-262.
18. Krivak TC, Elkas JC, Rose GS, et al. The utility of hand-
assisted laparoscopy in ovarian cancer. Gynecol Oncol. 2005;96:
72-76.
19. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of
diameter of largest residual disease on survival after primary
cytoreductive surgery in patients with suboptimal residual epi-
thelial ovarian carcinoma. Am J Obstet Gynecol. 1994;170:974-
980.
20. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz
FJ. Survival effect of maximal cytoreductive surgery for advanced
ovarian carcinoma during the platinum era: a meta-analysis.
J Clin Oncol. 2002;20:1248-1259.
21. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Dec-
loedt J, van Dam P. Neoadjuvant chemotherapy or primary
debulking surgery in advanced ovarian carcinoma: a retrospec-
tive analysis of 285 patients. Gynecol Oncol. 1998;71:431-436.
22. Fagotti A, Fanfani F, Ludovisi M, et al. Role of laparoscopy to
assess the chance of optimal cytoreductive surgery in advanced
ovarian cancer: a pilot study. Gynecol Oncol. 2005;96:729-735.
23. Angioli R, Palaia I, Zullo MA, et al. Diagnostic open laparos-
copy in the management of advanced ovarian cancer. Gynecol
Oncol. 2006;100:455-461.
24. Amara DP, Nezhat C, Teng NN, Nezhat F, Rosati M. Opera-
tive laparoscopy in the management of ovarian cancer. Surg
Laparosc Endosc. 1996;6:38-45.
25. Chi DS, Franklin CC, Levine DA, et al. Improved optimal
cytoreduction rates for stages IIIC and IV epithelial ovarian,
fallopian tube, and primary peritoneal cancer: a change in sur-
gical approach. Gynecol Oncol. 2004;94:650-654.
26. Nezhat CH, Nezhat F, Seidman DS, Nezhat C. Vaginal vault
evisceration after total laparoscopic hysterectomy. Obstet Gy-
necol. 1996 May;87(5 Pt 2):868-870.
27. Nezhat CH, Nezhat F, Nezhat C, Rottenberg H. Laparoscopic
repair of a vesicovaginal fistula: a case report. Obstet Gynecol.
1994 May;83(5 Pt 2):899-901.
28. Shakhar G, Ben Eliyahu S. Potential prophylactic measures
against postoperative immunosuppression: could they reduce
recurrence rates in oncological patients? Ann Surg Oncol. 2003;
10:972-992.
29. Allendorf JD, Bessler M, Whelan RL. Postoperative immune
function varies inversely with the degree of surgical trauma in a
murine model. Surg Endosc. 1997;11:427-430.
30. Evans C, Galustian C, Kumar D, Hagger R, Melville DM.
Impact of surgery on immunologic function: comparison be-
tween minimally invasive techniques and conventional laparot-
JSLS (2010)14:155–168 167omy for surgical resection of colorectal tumors. Am J Surg. 2009
Feb;197(2):238-245.
31. Smidt VJ, Singh DM, Hurteau JA, Hurd WW. Effect of carbon
dioxide on human ovarian carcinoma cell growth. Am J Obstet
Gynecol. 2001;185:1314-1317.
32. Abu-Rustum NR, Sonoda Y, Chi DS, et al. The effects of CO2
pneumoperitoneum on the survival of women with persistent
metastatic ovarian cancer. Gynecol Oncol. 2003;90:431-434.
33. Morice P, Camatte S, Larregain-Fournier D, Thoury A, Du-
villard P, Castaigne D. Port-site implantation after laparoscopic
treatment of borderline ovarian tumors. Obstet Gynecol. 2004;
104:1167-1170.
34. Nagarsheth NP, Rahaman J, Cohen CJ, Gretz H, Nezhat F.
The incidence of port-site metastases in gynecologic cancers.
JSLS. 2004;8:133-139.
The Safety and Efficacy of Laparoscopic Surgical Staging and Debulking of Apparent Advanced Stage Ovarian, Fallopian Tube, and
Primary Peritoneal Cancers, Nezhat FR et al.
JSLS (2010)14:155–168 168